NRAS G12C

CI-VAR-00001605Explore in graph →NP_002515.1:p.Gly12CysNM_002524.4:c.34G>TClinVar 40468 CIViC 897 rs121913250

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm4
NRAS G12C	Cetuximab	Predictive	D	Supports Resistance	—	submitted	EID3846 In an in vitro study, an OXCO-2 cell line expressing NRAS G12C mutation demonstrated acquired resistance after low level cetuximab exposure compared to OXCO-2 parental cells expressing NRAS wild-type.… (full text at CIViC) PMID 24553387 · Misale et al., 2014 · Open in CIViC	civic
NRAS G12C	Cetuximab + ChemotherapyCombination	Predictive	C	Supports Resistance	3	accepted	EID3845 Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
40468	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Chronic myeloid leukemia; Neoplasm; Embryonal rhabdomyosarcoma; Acute myeloid leukemia; NRAS-related disorder	germline/somatic	6	Oct 19, 2021	clinvar